Laurion Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Laurion Capital Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-886	Closed	-$214K	–	261
2025 Q2	$214K	Sell	886 -99	-10%	-$23.4K	﹤0.01%	339
2025 Q1	$240K	Buy	+985	New	+$296K	0.01%	224
2024 Q4	–	Sell	-959	Closed	-$321K	–	310
2024 Q3	$321K	Buy	+959	New	+$305K	﹤0.01%	226
2020 Q4	–	Sell	-440	Closed	-$227K	–	649
2020 Q3	$227K	Buy	+440	New	+$223K	﹤0.01%	731
2019 Q4	–	Sell	-12,643	Closed	-$4.21M	–	908
2019 Q3	$4.21M	Buy	+12,643	New	+$4.12M	0.03%	373
2019 Q2	–	Sell	-1,100	Closed	-$336K	–	905
2019 Q1	$336K	Buy	+1,100	New	+$297K	﹤0.01%	689
2017 Q3	–	Sell	-6,572	Closed	-$1.49M	–	1572
2017 Q2	$1.49M	Sell	6,572 -16,828	-72%	-$3.67M	0.01%	901
2017 Q1	$4.67M	Buy	+23,400	New	+$4.51M	0.04%	433

Other funds holding BIO

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Laurion Capital Management's BIO Position: Q3 2025 in Review

Laurion Capital Management sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2025, closing a stake of 886 shares — an estimated $214K sold.

Laurion Capital Management first reported a position in BIO in Q1 2017 and held it in 8 quarters. The position peaked at $4.67M in Q1 2017. 397 funds tracked by Wall St. Rank hold BIO as of Q3 2025.

Laurion Capital Management reported no remaining Bio-Rad Laboratories Class A position as of Q3 2025 after selling out during the quarter.
Laurion Capital Management sold 886 Bio-Rad Laboratories Class A shares in Q3 2025, an estimated $214K.
Laurion Capital Management first reported a position in Bio-Rad Laboratories Class A in Q1 2017 and held it in 8 quarters.
Laurion Capital Management's Bio-Rad Laboratories Class A position peaked at $4.67M in Q1 2017.
397 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2025.

Based on Laurion Capital Management's 13F filing for Q3 2025, filed 17 Nov 2025.